Antibody targeting of aging damaged isoDGR-protein doubles lifespan in a mouse model of chronic inflammation
Kalailingam, P.; Mohd-Kahliab, K.-H.; Ngan, S. C.; Iyappan, R.; Melekh, E.; Lu, T.; Zien, G. W.; Sharma, B.; Guo, T.; MacNeil, A. J.; Macpherson, R. E. K.; Tsiani, E. L.; O'Leary, D. D.; Lim, K. L.; Su, I. H.; Gao, Y.-G.; Richard, A. M.; Kalaria, R. N.; Chen, C. P.; McCarthy, N. E. K.; Sze, S. K.
Show abstract
Aging is the result of the accumulation of molecular damages that impair normal biochemical activities. We previously reported that aging-damaged amino acid sequence NGR (Asn-Gly-Arg) results in a gain-of-function conformational switching to isoDGR (isoAsp-Gly-Arg) motif. This integrin-binding motif activates leukocytes to induce chronic inflammation, which are characteristic features of age-linked cardiovascular disorders. We now report that anti-isoDGR immunotherapy doubles lifespan in mouse model of chronic inflammation. We observed extensive accumulation of isoDGR and inflammatory cytokine expression in multiple tissues from Pcmt1-KO and old WT animals, which could also be induced via injection of isoDGR-modified plasma proteins or synthetic peptides into young WT animals. However, weekly injection of anti-isoDGR mAb (1mg/kg) was sufficient to significantly reduce isoDGR-modified proteins and pro-inflammatory cytokine expression, improve behaviour and coordination, and double the average lifespan of Pcmt1-KO mice. Mechanistically, isoDGR-mAb mediated the immune clearance of damaged isoDGR-proteins by antibody-dependent cellular phagocytosis. These results indicate that immunotherapy targeting aging-damaged proteins may represent effective interventions for a range of age-linked degenerative disorders. Graphical Abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=105 SRC="FIGDIR/small/532237v1_ufig1.gif" ALT="Figure 1"> View larger version (12K): org.highwire.dtl.DTLVardef@81610borg.highwire.dtl.DTLVardef@a22aaorg.highwire.dtl.DTLVardef@169fe50org.highwire.dtl.DTLVardef@1b73d11_HPS_FORMAT_FIGEXP M_FIG Anti-isoDGR immunotherapy induces immune clearance of aging damaged isoDGR-proteins to reduce chronic inflammation, improve behaviour and coordination, and double lifespan in PCMT-/- mice. C_FIG
Matching journals
The top 1 journal accounts for 50% of the predicted probability mass.